ClinicalTrials.gg
RecruitingNCT07571746CLEAR-AbKDUpdated Oct 20, 2026

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

A Phase 2 interventional study of Surovatamig in Primary Membranous Nephropathy, sponsored by AstraZeneca. Recruiting at 27 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 20, 2026First site in ChinaPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Glomerulonephritis, Membranous with a site in United States — 13 open to participants now, 16 under way, 5 of them phase 3. Glomerulonephritis, Membranous · United States.

Planned enrollment
13th of 32
43 · median 31
Started
2026
with 3 others
Phase 2
11 of 35
6 open now
Primary completion
2028-10
later than 7 of 15 live
Registered
33rd of 35
by date
Lead sponsor
1 of 35
AstraZeneca

Among the 35 studies in Glomerulonephritis, Membranous with a site in United States, this one is the 13th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 7 of the 15 other live ones, and was the 33rd registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

13 of the 35 studies in Glomerulonephritis, Membranous with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Glomerulonephritis, Membranous with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.

Read the detailed description

This is a Phase II open-label study to assess the safety, tolerability, Pharmacokinetics, and efficacy of surovatamig in adult participants with pMN, who are positive for anti-PLA2R antibodies and have heavy and persistent proteinuria with a high risk of progressing to end stage kidney disease.

The study will be conducted across approximately 30 to 40 study sites in approximately 10 countries. The study consists of 2 parts (Part A Multiple ascending with sentinel dosing and Part B Multiple ascending doses), with each consisting of 3 periods (ie, screening period, treatment period, and follow-up period; up to 26 months in total).

03

Conditions studied

  • Primary Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age inclusive, at the time of signing the .
  2. Diagnosis of anti-PLA2R antibody-positive pMN.
  3. All participants must have received SoC therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for ≥ 4 weeks, with exceptions in case of intolerance, , or low blood pressure, before the screening period.
  4. Positive for anti-PLA2R.
  5. Up to date with required vaccinations as per institutional guidelines (eg, influenza, pneumococcal, and severe acute respiratory syndrome coronavirus 2) prior to study entry.
  6. Male and/or female assigned at birth, inclusive of all gender identities. use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  7. Capable of giving signed informed consent

Exclusion criteria

Exclusion Criteria:

  1. Receipt of B cell-depleting therapy including CD19- or CD20-directed monoclonal antibodies \< 9 months before screening.
  2. Immunomodulatory therapy \<3 months before screening.
  3. Secondary causes of membranous nephropathy
  4. Diabetes mellitus with > 8.5% tested at screening visit.
  5. History of HLH/MAS. 7 Significant CNS co-morbidity

8. History of chronic significant respiratory disease. 9. Significant opportunistic infection in the medical history deemed relevant by the Investigator.

10. Abnormal vital sign after 10 minutes sitting at rest. 11. Administration of such as prednisolone at doses exceeding 20 mg or an equivalent agent \< 2 months before screening.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    Surovatamig Arm

    Participants will receive Surovatamig

    Drug: Surovatamig

Interventions

  • Participants will receive Surovatamig subcutaneously

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events.

    To assess the safety and tolerability of surovatamig on adverse events, including Adverse events, Serious adverse events, Adverse event of special interests, and Adverse events leading to discontinuation of surovatamig.

    Time frame: Through study completion, an average of 2 years

  2. Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)

    To assess the effect of surovatamig on proteinuria

    Time frame: At 6 months

Secondary outcomes

  1. Percentage of participants achieving complete or partial remission of pMN

    To evaluate the proportion of participants who achieve partial and/or complete remission

    Time frame: At 24 months

  2. Percentage of participants achieving complete remission of pMN

    To evaluate the proportion of participants who achieved complete remission

    Time frame: At 24 months

  3. Percentage of participants achieving partial remission of pMN

    To evaluate the proportion of participants who achieve partial remission

    Time frame: At 24 months

  4. Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)

    To assess the effect of surovatamig on proteinuria

    Time frame: At 24 months

  5. Change from baseline in anti-PLA2R antibody titer

    To evaluate anti-PLA2R antibodies in blood

    Time frame: At 24 months

  6. Change from baseline in B-cell count in peripheral blood

    To assess the effect of surovatamig by assessment of B-cell depletion in blood

    Time frame: At 24 months

  7. Time to relapse after complete or partial remission

    Time to relapse after complete or partial remission

    Time frame: At 24 months

  8. Time to a ≥ 3 months sustained reduction of eGFR

    Time to a sustained reduction of eGFR

    Time frame: From Baseline to 24 months

  9. Change from baseline in patient-reported experience of symptoms associated with pMN

    To evaluate the change in patient-reported experience

    Time frame: Through study completion, an average of 2 years

  10. Serum PK parameters of surovatamig, AUC Area under the plasma concentration versus time curve

    To characterise the PK of surovatamig

    Time frame: Through study completion, an average of 2 years

  11. Treatment-emergent ADAs

    To evaluate the immunogenicity of surovatamig

    Time frame: Through study completion, an average of 2 years

  12. Serum PK parameters of surovatamig, as Cmax (Peak Plasma Concentration)

    To characterise the PK of surovatamig

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 of 27 sites recruiting
  • Research Site
    Los Angeles, California 90022, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Los Angeles, California 90095, United States
    Not yet recruiting
  • Research Site
    Iowa City, Iowa 52242, United States
    Not yet recruiting
  • Research Site
    Bethesda, Maryland 20889, United States
    Not yet recruiting
  • Research Site
    New York, New York 10016, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77027, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Not yet recruiting
  • Research Site
    Ieper, 8900, Belgium
    Not yet recruiting
  • Research Site
    Beijing, 100034, China
    Not yet recruiting
  • Research Site
    Beijing, 102218, China
    Not yet recruiting
  • Research Site
    Bordeaux, 33076, France
    Not yet recruiting
  • Research Site
    Créteil, 94010, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lyon, 69009, France
    Not yet recruiting
  • Research Site
    Nantes, 44093, France
    Not yet recruiting
  • Research Site
    Nîmes, 30029, France
    Not yet recruiting
  • Research Site
    Düsseldorf, 40225, Germany
    Not yet recruiting
  • Research Site
    Hanover, 30625, Germany
    Not yet recruiting
  • Research Site
    München, 80336, Germany
    Not yet recruiting
  • Research Site
    Brescia, 25123, Italy
    Not yet recruiting
  • Research Site
    Rozzano, 20089, Italy
    Not yet recruiting
  • Research Site
    Torino, 10154, Italy
    Not yet recruiting
  • Research Site
    Verona, 37126, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lodz, 92-213, Poland
    Not yet recruiting
  • Research Site
    Barcelona, 08025, Spain
    Not yet recruiting
  • Research Site
    Madrid, 28041, Spain
    Not yet recruiting
  • Research Site
    London, NW3 2PF, United Kingdom
    Not yet recruiting
  • Research Site
    Manchester, M13 9WL, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Apr 2028 → Oct 2028 and completion Oct 2029 → Apr 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
May 6, 2026
StartActual
Mar 28, 2026
Primary completionEst.
Oct 13, 2028was Apr 2028
CompletionEst.
Apr 15, 2030was Oct 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in China
Show 3 added (2 China, 1 Germany)
  • Research Site · Beijing, China
  • Research Site · Beijing, China
  • Research Site · Hanover, Germany
Oct 20, 2026
Primary completion
Apr 24, 2028→Oct 13, 2028
Oct 20, 2026
Study completion
Oct 15, 2029→Apr 15, 2030
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    3 sites added — first site in China
    Show 3 added (2 China, 1 Germany)
    • Research Site · Beijing, China
    • Research Site · Beijing, China
    • Research Site · Hanover, Germany
    Primary completion Apr 24, 2028→Oct 13, 2028
    Study completion Oct 15, 2029→Apr 15, 2030
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07571746
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Mar 28, 2026
Primary completion
Oct 13, 2028 (estimated)
Completion
Apr 15, 2030 (estimated)
Last update
Oct 20, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Surovatamig

Start the discussion